Introducing a Genomic-Centered ETF

Jim Woods

Jim Woods has over 20 years of experience in the markets from working as a stockbroker, financial journalist, and money manager.
[prescription pills in a rising bar graph on $100 bills]

While the Delta variant of COVID-19 is getting all the headlines right now, the frontiers of biotechnology are not solely confined to treating the outbreak of this pathogen.


Indeed, a great deal of effort and money is being poured into developing treatments for genomic diseases like cystic fibrosis. As there are many genomic-related biotech companies out there, each claiming to have the next “big cure” for the disease du jour, some investors might want to turn to the Global X Genomics & Biotechnology Exchange-Traded Fund (NASDAQ: GNOM) as an alternative to owning possibly volatile individual biotechnology stocks.

The stocks in this exchange-traded fund’s (ETF) portfolio are selected from a list of companies that obtain more than 50% of their revenue from gene editing, genomic sequencing, the development and testing of genetic medicines, computational genomics or biotechnology. To calculate this figure, the fund uses a natural language processing algorithm that scans public documents, including filings and disclosures, and then makes the necessary selections.

Currently, the fund’s top holdings include Intellia Therapeutics, Inc. (NASDAQ: NTLA), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Genscript Biotech Corporation (HKG: 1548), Agilent Technologies, Inc. (NYSE: A), QIAGEN NV (NYSE: QGEN), CareDx, Inc. (NASDAQ: CDNA), Natera, Inc. (NASDAQ: NTRA) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)


This fund’s performance has been relatively mixed, even when including the damage done by the COVID-19 pandemic. As of July 27, GNOM was down 7.68% over the past month and down 6.03% for the past three months. It is currently down 6.31% year to date.

Exclusive  Three Cryptocurrency Investments to Buy as Bitcoin Hits a Five-Month Low

Chart courtesy of

The fund has amassed $244.2 million in assets under management and has an expense ratio of 0.50%.


While GNOM does provide an investor with a way to profit from genomic technology, this kind of ETF may not be appropriate for all portfolios. Thus, interested investors always should conduct their due diligence and decide whether the fund is suitable for their investing goals.

As always, I am happy to answer any of your questions about ETFs, so do not hesitate to send me an email. You just may see your question answered in a future ETF Talk.

share on:

Like This Article?
Now Get Jim's FREE Special Report:
The Top 11 Dividend ETFs to
Buy Right Now

Get up to 5X the yields of traditional income plays.

Get Access to the Report, 100% FREE

share on:


Dr. Mark Skousen

Named one of the "Top 20 Living Economists," Dr. Skousen is a professional economist, investment expert, university professor, and author of more than 25 books.

Product Details

  • Forecasts & Strategies
  • Home Run Trader
  • Fast Money Alert
  • Five Star Trader
  • TNT Trader

Bryan Perry

A former Wall Street financial advisor with three decades' experience, Bryan Perry focuses his efforts on high-yield income investing and quick-hitting options plays.

Product Details

  • Cash Machine
  • Premium Income PRO (exclusively for subscribers of Cash Machine)
  • Quick Income Trader
  • Breakout Options Alert
  • Hi-Tech Trader

Jim Woods

Jim Woods has over 20 years of experience in the markets from working as a stockbroker,
financial journalist, and money manager. As well as a book author and regular contributor to
numerous investment websites, Jim is the editor of:

Product Details

  • Successful Investing
  • High Velocity Options
  • Intelligence Report
  • Bullseye Stock Trader
  • Eagle Eye Opener

Bob Carlson

Bob Carlson provides independent, objective research covering all the financial issues of retirement and retirement planning. In addition, Bob serves as Chairman of the Board of Trustees of the Fairfax County (VA) Employees’ Retirement System, which has over $2.8 billion in assets.

Product Details

  • Retirement Watch
  • Retirement Watch Spotlight Series
  • Lifetime Retirement Protection Program

Jon Johnson

Jon Johnson's philosophy in investing and trading is to take what the market gives you regardless if that is to the upside or downside. For the past 21 years, Jon has helped thousands of clients gain success in the financial markets through his newsletters and education services:

Product Details

  • Investment House Daily
  • Stock of the Week
  • Technical Traders Alert
  • Rapid Profits Stock Trader

Used by financial advisors and individual investors all over the world, is the premier provider and one-stop shop for dividend information and research.

Product Details

Popular tools include our proprietary Dividend Calendar, Dividend Calculator, Dividend Score Card, and many more.

  • Dividend Investor

George Gilder

George Gilder is the most knowledgeable man in America when it comes to the future of technology and its impact on our lives.  He’s an established investor, bestselling author, and economist with an uncanny ability to foresee how new breakthroughs will play out, years in advance.

Product Details

  • Technology Report
  • Technology Report PRO
  • Moonshots
  • Private Reserve
  • Millionaire Circle


DayTradeSPY was founded by head trader Hugh Grossman, a retired internal auditor for a Fortune 500 company. After years of first-hand experience trying out one trading strategy after another, Hugh instead developed his own trading system centered around day trading SPY options. That’s it... Nothing else.

Product Details

  • Trading Room
  • Pick of the Day
  • Inner Circle
  • Online Workshops